Global Pulmonary Arterial Hypertension (PAH) Market Research Report 2019

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Pulmonary Arterial Hypertension (PAH) Revenue
• 1.4 Market by Type
  • 1.4.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Prostacyclin and Prostacyclin Analogs
  • 1.4.3 SGC Stimulators
  • 1.4.4 ERA
  • 1.4.5 PDE-5
• 1.5 Market by Application
  • 1.5.1 Global Pulmonary Arterial Hypertension (PAH) Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital
  • 1.5.3 Clinic
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Pulmonary Arterial Hypertension (PAH) Market Perspective (2015-2026)
• 2.2 Global Pulmonary Arterial Hypertension (PAH) Growth Trends by Regions
  • 2.2.1 Pulmonary Arterial Hypertension (PAH) Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Pulmonary Arterial Hypertension (PAH) Historic Market Share by Regions (2015-2020)
  • 2.2.3 Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Pulmonary Arterial Hypertension (PAH) Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Pulmonary Arterial Hypertension (PAH) Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Market Size
  • 3.1.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue (2015-2020)
  • 3.1.2 Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Pulmonary Arterial Hypertension (PAH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio
  • 3.2.1 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Revenue in 2019
• 3.3 Pulmonary Arterial Hypertension (PAH) Key Players Head office and Area Served
• 3.4 Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
• 3.5 Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Type (2015-2020)
• 4.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)
• 5.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
• 6.2 Pulmonary Arterial Hypertension (PAH) Key Players in North America (2019-2020)
• 6.3 North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
• 6.4 North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
• 7.2 Pulmonary Arterial Hypertension (PAH) Key Players in Europe (2019-2020)
• 7.3 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
• 7.4 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

8 China

• 8.1 China Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
• 8.2 Pulmonary Arterial Hypertension (PAH) Key Players in China (2019-2020)
• 8.3 China Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
• 8.4 China Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
• 9.2 Pulmonary Arterial Hypertension (PAH) Key Players in Japan (2019-2020)
• 9.3 Japan Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
• 9.4 Japan Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
• 10.2 Pulmonary Arterial Hypertension (PAH) Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
• 10.4 Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

11 India

• 11.1 India Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
• 11.2 Pulmonary Arterial Hypertension (PAH) Key Players in India (2019-2020)
• 11.3 India Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
• 11.4 India Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
• 12.2 Pulmonary Arterial Hypertension (PAH) Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
• 12.4 Central & South America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Actelion
  • 13.1.1 Actelion Company Details
  • 13.1.2 Actelion Business Overview
  • 13.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Introduction
  • 13.1.4 Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020))
  • 13.1.5 Actelion Recent Development
• 13.2 Gilead Sciences
  • 13.2.1 Gilead Sciences Company Details
  • 13.2.2 Gilead Sciences Business Overview
  • 13.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Introduction
  • 13.2.4 Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
  • 13.2.5 Gilead Sciences Recent Development
• 13.3 United Therapeutics
  • 13.3.1 United Therapeutics Company Details
  • 13.3.2 United Therapeutics Business Overview
  • 13.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Introduction
  • 13.3.4 United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
  • 13.3.5 United Therapeutics Recent Development
• 13.4 GlaxoSmithKline
  • 13.4.1 GlaxoSmithKline Company Details
  • 13.4.2 GlaxoSmithKline Business Overview
  • 13.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Introduction
  • 13.4.4 GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
  • 13.4.5 GlaxoSmithKline Recent Development
• 13.5 Pfizer
  • 13.5.1 Pfizer Company Details
  • 13.5.2 Pfizer Business Overview
  • 13.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Introduction
  • 13.5.4 Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
  • 13.5.5 Pfizer Recent Development
• 13.6 Bayer
  • 13.6.1 Bayer Company Details
  • 13.6.2 Bayer Business Overview
  • 13.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Introduction
  • 13.6.4 Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
  • 13.6.5 Bayer Recent Development
• 13.7 Arena
  • 13.7.1 Arena Company Details
  • 13.7.2 Arena Business Overview
  • 13.7.3 Arena Pulmonary Arterial Hypertension (PAH) Introduction
  • 13.7.4 Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
  • 13.7.5 Arena Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer